Diabetic Neuropathy Market Report 2026

Diabetic Neuropathy Market Overview

• Diabetic Neuropathy market size has reached to $6.21 billion in 2025 • Expected to grow to $10.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.4% • Growth Driver: Rising Diabetes Prevalence Sparks Growth In Diabetic Neuropathy Market • Market Trend: Innovative Advancements In Diabetic Neuropathy Treatment Are Exemplified By The Neuromodulation Therapy Device • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Diabetic Neuropathy Market?

Diabetic neuropathy is a type of nerve damage that can occur in people with diabetes. High blood sugar levels induce it, which can damage the blood vessels. It can harm various nerves in the body, including those in the feet, organs, and muscles. The main disorders of diabetic neuropathy are peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral neuropathy is a disorder that occurs when the peripheral nerves, which carry information to and from the brain and spinal cord to the rest of the body, are damaged. The various classes of drugs used for diabetic neuropathy are analgesics, anti-depressants, anti-convulsant, and others, which involve drug treatment, radiotherapy, physiotherapy, and others. These are provided through several distribution channels, such as online distribution and offline distribution, which are used in hospitals, specialty clinics and others.

What Is The Diabetic Neuropathy Market Growth Forecast?

The diabetic neuropathy market size is expected to see rapid growth in the next few years. It will grow to $10.14 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to development of targeted neuropathy drugs, expansion of early diagnostic tools, increasing patient screening, growth in specialty neurology clinics, demand for improved quality of life. Major trends in the forecast period include increasing use of neuropathic pain medications, rising focus on early nerve damage detection, expansion of combination drug therapies, growing adoption of symptom management approaches, increased patient awareness and diagnosis rates.

Global Diabetic Neuropathy Market Segmentation

1) By Disorder: Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy 2) By Drug Class: Analgesics, Anti-Depressants, Anti-Convulsants, Other Drug Classes 3) By Treatment: Drug Treatment, Radiotherapy, Physiotherapy, Other Treatments 4) By Distribution Channel: Online Distribution, Offline Distribution 5) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Peripheral Neuropathy: Distal Symmetric Neuropathy, Mononeuropathy, Polyneuropathy 2) By Autonomic Neuropathy: Cardiovascular Autonomic Neuropathy, Gastrointestinal Autonomic Neuropathy, Genitourinary Autonomic Neuropathy 3) By Proximal Neuropathy: Diabetic Amyotrophy, Lumbosacral Plexus Neuropathy 4) By Focal Neuropathy: Cranial Neuropathy, Cervical Radiculopathy

What Is The Driver Of The Diabetic Neuropathy Market?

The rising prevalence of diabetes is expected to boost the growth of the diabetic neuropathy market going forward. Diabetes is a persistent disorder where the body struggles to use and store glucose appropriately (a type of sugar). Diabetes occurs when the body either does not create enough insulin (a hormone that aids in blood sugar regulation) or does not use insulin effectively. Diabetic neuropathy is a type of nerve injury that can occur in diabetics with d different forms of nerve damage causing different symptoms. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international not-for-profit federation of national diabetes associations, an estimated 589 million adults aged 20–79 were living with diabetes worldwide, with that number projected to reach 853 million by 2050. Therefore, the rising prevalence of diabetes is driving the growth of the diabetic neuropathy industry.

Key Players In The Global Diabetic Neuropathy Market

Major companies operating in the diabetic neuropathy market are Pfizer Inc., Eli Lilly and Company, Daiichi Sankyo Company Limited, Johnson & Johnson, Depomed Inc., F. Hoffmann-La Roche AG, NeuroMetrix Inc, Lupin Limited, Novartis AG, Boehringer Ingelheim, Regenacy Pharmaceuticals Inc., Merck & Co. Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Merck KGaA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Zydus Cadila, Genentech Inc.

Global Diabetic Neuropathy Market Trends and Insights

Major companies operating in the diabetic neuropathy market are innovating advanced products, such as the neuromodulation therapy device, to enhance treatment options for patients suffering from chronic pain associated with diabetic neuropathy. Neuromodulation therapy devices for diabetic neuropathy offer non-invasive treatment options by modulating nerve activity to relieve pain, improve nerve function, and promote healing in patients with diabetic nerve damage. For instance, in January 2024, Neuralace Medical, Inc., a US-based company that provides non-drug pain management treatment, received approval from the Food and Drug Administration (FDA), a US-based federal agency for Axon Therapy for Chronic Painful Diabetic Neuropathy. Axon Therapy device is designed to treat chronic painful diabetic neuropathy (CPDN). This innovative therapy utilizes neuromodulation techniques to provide relief from pain associated with diabetic neuropathy, marking a significant advancement in pain management options for patients suffering from this condition. The clearance underscores the device's safety and efficacy, allowing Neuralace to move forward with commercialization and expand access to effective treatment solutions for those affected by CPDN.

What Are Latest Mergers And Acquisitions In The Diabetic Neuropathy Market?

In December 2023, Celeri Research Group, a US-based clinical-research and real-world-evidence company, partnered with Averitas Pharma, Inc. to conduct a post-market, multi-center observational study evaluating treatment outcomes in neuropathic pain. With this partnership, Celeri Research Group and Averitas Pharma aim to generate robust real-world evidence on the effectiveness of the QUTENZA high-concentration capsaicin patch in adults with painful diabetic peripheral neuropathy, improve clinical understanding of patient-reported outcomes, and support long-term optimization of neuropathic pain management. Averitas Pharma, Inc. is a US-based specialty pharmaceutical company focused on developing and commercializing innovative, non-opioid therapies for neuropathic pain and other chronic pain conditions.

Regional Outlook

North America was the largest region in the diabetic neuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the diabetic neuropathy market during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Diabetic Neuropathy Market?

The diabetic neuropathy market consists of sales of drugs such as anticonvulsants, pain medications, nerve growth factor inhibitors and other drugs that are used to treat the symptoms of nerve damage caused by diabetes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Diabetic Neuropathy Market Report 2026?

The diabetic neuropathy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic neuropathy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.